Corporate Update from Q-Therapeutics: IND Filing for ALS Targeted for 2014

Salt Lake City, Utah-based Q-therapeutics has released its formal corporate update on the research and development status of the company. Q Therapeutics is developing a cell-based therapeutic product, called Q-cellsĀ®, to restore or preserve normal neuronal function by replacing astrocytes, and oligendendrocytes, the “support” cells of the nervous system. In 2013, Q-Therapeutics obtained Orphan Drug Designation from the FDA for Q-Cells for treating ALS, which provides financial incentives and regulatory support for developing these cells into an ALS therapy. The company aims to complete investigational new drug (IND)-enabling studies required by the FDA for initiation of clinical trials in 2014.

Click here to read about Q-therapeutics’ latest progress.

Share this: